

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

**Neuroendocrine effects of citalopram, a selective serotonin re-uptake inhibitor, during life span in humans**

**This is the author's manuscript**

*Original Citation:*

*Availability:*

This version is available <http://hdl.handle.net/2318/75213> since 2016-10-28T15:08:16Z

*Published version:*

DOI:10.3275/6994

*Terms of use:*

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

# Neuroendocrine effects of citalopram, a selective serotonin re-uptake inhibitor, during lifespan in humans

R. Berardelli<sup>1</sup>, E. Margarito<sup>2</sup>, F. Ghiggia<sup>2</sup>, A. Picu<sup>1</sup>, M. Balbo<sup>1</sup>, L. Bonelli<sup>1</sup>, R. Giordano<sup>3</sup>, I. Karamouzis<sup>1</sup>, M. Bo<sup>2</sup>, E. Ghigo<sup>1</sup>, and E. Arvat<sup>1</sup>

<sup>1</sup>Division of Endocrinology and Metabolism, Department of Internal Medicine; <sup>2</sup>Department of Medical and Surgical Disciplines, Sections of Geriatrics; <sup>3</sup>Department of Clinical and Biological Science, University of Turin, Turin, Italy

**ABSTRACT.** *Objective:* Serotonergic system contributes to the regulation of hypothalamus-pituitary-adrenal axis. In humans, serotonergic agonists increase PRL, ACTH, and cortisol, while serotonin (5HT) influence on GH is controversial. Central 5HT activity and neuroendocrine function change during lifespan. *Design:* To clarify the neuroendocrine response to 5HT across lifespan, we assessed ACTH, cortisol, DHEA, PRL, and GH responses to citalopram (CT) in young adults (YA) (no.=12, 29.2±1.7 yr mean±SEM), middle aged (MA) (no.=12, 54.3±0.9 yr), and elderly (ES) (no.=12, 69.3±0.9 yr) males. All the subjects received placebo (saline iv over 120 min) or CT (20 mg iv over 120 min). Blood samples were taken every 15 min up to 240 min. *Results:* During placebo, ACTH, cortisol, GH, and PRL were similar in all groups while DHEA

showed an age-dependent reduction from middle age ( $p<0.001$ ). During CT, ACTH, and cortisol were higher than during placebo in YA ( $p<0.05$ ) and even more in MA ( $p<0.01$  vs placebo,  $p<0.05$  vs YA); in ES, the increase of both ACTH and cortisol ( $p<0.05$  vs placebo) was lower than in MA ( $p<0.05$ ) and higher than in YA ( $p<0.05$  for cortisol only). No changes were observed for DHEA, GH, and PRL in any group. *Conclusions:* Corticotrope response to CT is age-dependent in normal men, being amplified starting from middle age, suggesting precocious changes in the serotonergic neuroendocrine control during lifespan. CT is a useful tool to evaluate the age-dependent serotonergic function in humans. (J. Endocrinol. Invest. 33: 657-662, 2010)

©2010, Editrice Kurtis

## INTRODUCTION

Serotonergic system is known to play a central role in the regulation of neuroendocrine activity in animals and humans (1, 2). There is evidence that it is involved in the mediation of the hippocampal feedback regulation of the hypothalamus-pituitary-adrenal (HPA) axis. In fact, *in vitro* studies showed that serotonin (5HT) increases hippocampal mRNA expression of glucocorticoid receptors, in culture cells of rats, mice, and guinea pigs especially during certain periods of fetal life (3-5). In the hypothalamic paraventricular nucleus, direct synaptic connections between serotonergic neurons and CRH-secreting neurons have also been demonstrated (6) and, at this level, 5HT exerts an excitatory effect on the CRH secretion, with a resulting increase in ACTH and cortisol circulating levels (7). The activation of both 5HT<sub>2c</sub> (8) and 5HT<sub>1A</sub>/5HT<sub>2A</sub> receptors seems to mediate these neuroendocrine effects of 5HT (9-11).

In humans, serotonergic agonists have been shown to increase PRL, ACTH, and cortisol levels after acute administration (12-14) while the role of 5HT on GH secretion in physiological conditions is less clear (12, 13).

Based on this evidence, neuroendocrine challenge tests with serotonergic agonists have been often used to investigate the activity of the serotonergic system in both

physiological and pathological conditions. The latter include psychiatric disorders, such as major depression and eating disorders, in which an impairment of serotonergic system as well as a central HPA hyperactivity have been demonstrated by most of the Authors (12, 13).

Besides psychiatric disorders, another condition characterized by serotonergic impairment and HPA alterations is aging, in which a decrease in 5HT concentrations has been demonstrated (15, 16). Many studies have also emphasized the existence of receptor loss in this period of life, as pointed out by both *post mortem* and *in vivo* analyses (17, 18) by using 5HT ligands and neuroimaging (19-21). The extent of 5HT receptor loss is reported to be 10-17% "per decade" starting from the levels at 20 yr of age (20-22). The most involved receptor subtypes are 5HT<sub>1A</sub> and 5HT<sub>2A</sub>, while no clear reduced affinity of the remaining receptors has been described (20-23). Indeed, Sheline and co-workers (21) have shown that the age-related serotonergic receptor loss (especially for 5HT<sub>2A</sub>) is greatest in middle age, then levelling off after the 5<sup>th</sup> decade, in widely scattered brain regions, including the hippocampus. This suggests that middle age is a crucial period of life for the change in the neuroendocrine control of 5HT. A decline in central 5HT activity, expressed as a reduced PRL response to both 5HT releasing agents and receptor agonists, has also been shown in elderly subjects (24-26). Moreover, a recent work indicated a positive correlation between allelic variants of the 5HT transporter gene, morning cortisol concentrations, and cognitive impairment in a population of elderly subjects (27), thus emphasizing the link between serotonergic activity, HPA axis, and brain function in aging.

Since the serotonergic probes used so far have been criticized with respect to their limited specificity for sero-

**Key-words:** ACTH, citalopram, cortisol, DHEA, lifespan, SSRI.

**Correspondence:** E. Arvat, MD, Division of Endocrinology and Metabolism, Department of Internal Medicine, Ospedale San Giovanni Battista-Molinette, C.so Dogliotti 14, 10126 Turin, Italy.

**E-mail:** emanuela.arvat@unito.it

Accepted November 30, 2009.

First published online April 22, 2010.

tonergic system (28, 29), or raise safety concerns, as in the case of fenfluramine (30, 31), some authors have suggested citalopram (CT), a specific 5HT reuptake inhibitor (SSRI), as a suitable neuroendocrine probe to investigate the serotonergic function (14, 28-34).

In order to clarify the neuroendocrine effects of 5HT across lifespan, in the present study we assessed the responses of ACTH, cortisol, DHEA, PRL, and GH to iv CT administration in a group of healthy young, middle aged and elderly volunteers. In fact, while middle age is probably a crucial period of life for the changes in the serotonergic activity, the majority of previous studies evaluated the age-related neurohormonal response to 5HT selectively comparing young and elderly people only.

## SUBJECTS AND METHODS

### Subjects

Twelve male young adults (YA) [age  $29.2 \pm 1.7$  yr mean  $\pm$  SEM, body mass index (BMI)  $22.3$  kg/m<sup>2</sup>], 12 male middle aged (MA) ( $54.3 \pm 0.9$  yr, BMI  $23.7$  kg/m<sup>2</sup>) and 12 male elderly (ES) ( $69.3 \pm 0.9$  yr, BMI  $24.2$  kg/m<sup>2</sup>) subjects were studied. All the subjects were screened to exclude acute physical illness or any acute or prior psychiatric disorder by physical examination, laboratory testing, and structured interview. None of the subjects had history of alcohol, substance dependence or recent stress events. They had been free of any drug known to influence HPA axis and serotonergic system, especially antidepressants or neuroleptics, for at least 3 months before the study. The study protocol had been approved by an independent, local Ethics Committee and written, informed consent was obtained from all subjects.

### Study design

All the subjects were randomized to receive placebo (saline iv over 120 min) or CT (20 mg iv over 120 min) with a 1-week washout between treatments. CT infusion was slower than in previous studies, in order to avoid side effects (like nausea, sickness, dizziness, distress, and restlessness) experienced with faster infusions (10 or 20 mg over 15-30 min) (28, 30, 35, 36).

After an overnight fasting, the tests began in the morning at 08:30-09:00 h, 30 min after an indwelling catheter had been placed into an antecubital vein of the forearm, that was maintained patent until the end of the study by slow infusion of isotonic saline.

Blood samples were taken every 15 min from 0 (starting of place-

bo or CT infusion) to +240 min for all the subjects. ACTH, cortisol, DHEA, PRL, and GH levels were analyzed at each time point.

### Hormone measurements

Plasma ACTH levels (pg/ml) were measured in duplicate by an immunoradiometric assay (IRMA CTK, DiaSorin, Vercelli, Italy). The sensitivity of the assay was 1.2 pg/ml. The range of inter- and intra-assay coefficients of variations were 4.4-16.2% and 1.3-7.9%, respectively.

Serum cortisol levels ( $\mu$ g/l) were measured in duplicate by a radioimmunoassay (RIA, Immunotech, France). The sensitivity of the assay was 3.62  $\mu$ g/l. The range of inter- and intra-assay coefficients of variations were 5.3-9.2% and 2.8-5.8%, respectively.

Serum DHEA levels ( $\mu$ g/l) were measured in duplicate by a radioimmunoassay (RIA, Chematil, Webster, Texas, USA). The sensitivity of the assay was 0.09  $\mu$ g/l. The range of inter- and intra-assay coefficients of variations were 10.68-13.72% and 5.2-6.4%, respectively.

Serum GH levels ( $\mu$ g/l) were measured in duplicate by an immunoradiometric assay (IRMA CT, Radim, Pomezia, Italy). The sensitivity of the assay was 0.04  $\mu$ g/l. The range of inter- and intra-assay coefficients of variations were 4.6% and 3.7%, respectively.

Serum PRL levels ( $\mu$ g/l) were measured in duplicate by an immunoradiometric assay (IRMA, Immunotech, France). The sensitivity of the assay was 0.5  $\mu$ g/l. The range of inter- and intra-assay coefficients of variations were 6.2-8.0% and 1.6-2.8%, respectively.

### Statistical analysis

Hormonal responses are expressed as mean, SEM, and relative 95% confidence interval (95% CI) of either absolute values or area under curves (AUC) calculated by trapezoidal integration. For each subject the differences between placebo and CT were computed at each time point and analysis of variance for repeated measures model (Greenhouse-Geisser estimation) was used to analyse the variation of the differences among YA, MA, and ES subjects in the 4 h of hormonal evaluation. Variations between placebo and CT effects at each time point and differences between YA, MA, and ES subjects (separately for placebo and CT) were compared by means of non-parametric Wilcoxon and Mann-Whitney test, respectively. Differences with a  $p$ -value  $< 0.05$  were considered statistically significant. SPSS (Statistical Package for the Social Science), version 15.0 was used for the analysis.




Fig. 1 - ACTH, cortisol, and DHEA levels (mean  $\pm$  SEM) during placebo in young adults (YA), middle aged (MA), and elderly (ES) subjects.

Table 1 - GH, PRL, and DHEA area under curves (AUC)<sub>0-240</sub>±SEM during placebo or citalopram infusion in young adults (YA), middle aged (MA) and elderly (ES) subjects.

AUC <sub>0-240</sub> ±SEM	YA	MA	ES
Placebo			
GH µg/l/h	183.8±111.8	172.6±115.4	142±14.9
PRL µg/l/h	1251.3±195.3	1140.5±88.1	1082.8±8.1
DHEA µg/l/h	2358.2±191.3	838.3±94.4	704.5±62.5
Citalopram			
GH µg/l/h	209.1±60.7	194.3±132.3	169.9±17.3
PRL µg/l/h	1299.9±333.5	1184.5±101.2	1123.4±94.4
DHEA µg/l/h	2416.4±158.4	865.8±211.4	749.8±109.3

**RESULTS**

During placebo session, a trend toward a decrease in the ACTH and cortisol levels were observed in all groups, without any significant difference recorded between each group (Fig. 1). On the contrary, DHEA levels were significantly higher ( $p<0.001$ ) in YA compared to MA and ES at each time point; the two latter groups showed similar hormonal levels (Fig. 1). There were no statistically significant differences among the groups for GH and PRL levels (Table 1).

Looking at the CT effect, in YA ACTH concentrations were significantly increased by CT starting from time point 60 min up to 120 min ( $p<0.05$ ) compared to the same time points during placebo session; cortisol secretion reached a significant increase ( $p<0.05$ ) at 30 min, 45, and 60 min (Fig. 2). In MA, CT significantly increased ACTH starting from 15 min up to 165 min ( $p<0.01$ ) and cortisol from 30 min up to 195 min ( $p<0.01$ ) compared

to placebo session (Fig. 2). In ES, ACTH levels were also significantly higher during CT ( $p<0.01$ ) than during placebo, starting from 45 min up to 135 min, while cortisol levels were increased from 45 min up to 75 min ( $p<0.05$ ) (Fig. 2).

No significant differences in GH, PRL, and DHEA secretion were observed between CT and placebo session in any group, although DHEA levels showed a trend toward increase during CT, especially in MA group (Table 1).

For CT session, an interaction effect of group has been recorded. YA vs MA: ACTH levels were significantly higher in MA from 30 min up to 90 min ( $p<0.05$ ), while cortisol showed an even higher significant increase in MA, starting from 15 min to 195 min ( $p<0.01$ ) (Fig. 3). YA vs ES: no differences were observed for ACTH, while cortisol was significantly higher in ES from 15 min up to 75 min ( $p<0.05$ ) (Fig. 3). MA vs ES: ACTH levels were higher in MA from 15 min to 90 min and at 225 min and 240 min ( $p<0.01$ ), while cortisol showed a significant higher increase in MA from time 60 min to time 180 min ( $p<0.05$ ) (Fig. 3).

The statistical difference recorded for DHEA levels, which was higher at every time point in YA with respect to MA and ES ( $p<0.001$ ) simply reflected the higher levels in YA already observed during placebo, as no response to CT has been shown in any group (Table 1). There were no statistically significant differences among the groups for GH and PRL levels (Table 1).

**Side effects**

CT administration induced a transient local discomfort (burning sensation at the beginning of the infusion) in 1 YA and 2 ES.




Fig. 2 - ACTH and cortisol levels (mean±SEM) in young adults (YA), middle aged (MA), and elderly (ES) subjects during placebo and citalopram (CT) infusion.




Fig. 3 - ACTH and cortisol levels (mean $\pm$ SEM) during citalopram (CT) infusion in young adults (YA), middle aged (MA), and elderly (ES) subjects.

## DISCUSSION

The results of our study demonstrate an age-dependent stimulatory effect of CT on corticotrope secretion in normal men. In fact, both ACTH and cortisol levels were significantly increased by acute CT infusion in YA, MA, and ES subjects, but a transient HPA hyper-responsiveness to CT has been recorded in MA, with hormonal levels clearly higher than in YA and ES subjects. Our findings also showed that DHEA secretion is clearly reduced starting from middle age, with no response to SSRI administration. Conversely, basal lactotrope and somatotrope activities were similar in all groups and no response to CT was observed in any period of adult life.

An age-related hyperactivation of HPA axis has been shown in both animals and humans, as demonstrated by the evidence of an increase in both basal and stimulated ACTH and cortisol concentrations in aging (37-40). However, some studies failed to observe any significant effect of age on either ACTH or cortisol levels (41-44) or even showed a decreased basal cortisol secretion with advancing age (45, 46). In agreement with these studies, we did not observe any significant age-related difference in term of morning basal ACTH and cortisol levels. This is not surprising, considering that the hyperactivation of HPA axis in the elderly is mostly occurring not at the peak

level but rather during the nadir of the circadian rhythm, likely reflecting the age-related reduction in the negative feedback action of circulating glucocorticoids (37-39).

In humans, a stimulatory effect on both ACTH and cortisol secretion has been demonstrated after acute administration of several serotonergic agonists (12-14, 32). CT has been shown as a selective SSRI, with no known intrinsic activity at 5HT receptors or other receptor families (28, 30, 32) and it has been suggested as a suitable neuroendocrine probe to evaluate the central serotonergic activity (14, 28-34). The SSRI-induced inhibition of 5HT reuptake increases 5HT levels in the synaptic cleft, thereby prolonging the activation of post-synaptic 5HT receptors. We have previously demonstrated that acute serotonergic stimulation by citalopram increases ACTH and PRL levels in normal young subjects while some alterations in the neuroendocrine response to this compound was present in anorexic patients (47).

While a reduction in 5HT function as well as a derangement in the neuroendocrine response to 5HT has been demonstrated in aging, little information is available about the period of life in which serotonergic neuroendocrine activity starts to change.

Our findings showed that the corticotrope response to SSRI clearly changes across lifespan in normal men, starting



from middle age. The ACTH and cortisol responses to CT were, in fact, clearly amplified in MA subjects, whereas only cortisol response was significantly increased in aged subjects, in comparison with YA. These results seem, apparently, in contrast with the progressive reduction of 5HT function observed with advancing age and, especially, with the evidence of a marked 5HT receptors loss in middle age (20-22). Nevertheless, it may be hypothesized that, during this period of life, the 5HT receptor loss in the synaptic cleft leads to an up-regulation of the remaining receptors, with a resulting temporary hypersensitivity to serotonergic challenges. On the other hand, the progressive reduction in the HPA response to CT from middle to advanced age agrees with the hypothesis that the up-regulation mechanism is turned-off with advancing age, probably reflecting an age-related sensitivity loss of the remaining receptors. Moreover, a reduction of 5HT concentrations and/or a decrease in 5HT transporter concentrations, demonstrated in aged brain (15, 16), could also explain the progressive reduction in the HPA response to CT from middle to advanced age observed in our study.

Taking into account the evidence of the age-related decline in the brain 5HT activity, the basically similar HPA response to CT, in our YA and ES subjects was quite unexpected and not easy to explain. At a first glance, this finding could allow to state that advanced age may have no major impact on SSRI-induced HPA stimulation. However, the lack of remarkable difference in the hormonal response between YA and ES, observed in our study, may be consistent with the reduced responsiveness of the HPA axis to the negative feedback of the ES, leading to a relative HPA hyperactivity, which may mask the age-related decline in the 5HT function.

Moreover, in both YA and ES subjects, but not in MA, the adrenal response to CT was slightly anticipated or concomitant with the corticotrope response to the drug; this hormonal pattern is not usual for central stimulations which normally release ACTH before cortisol (48). Although SSRI receptors have been identified in both normal and hyperplastic adrenal gland, data in humans showed a direct stimulatory effect of SSRI in bilateral ACTH-independent bilateral macronodular adrenal hyperplasia only, possibly reflecting the increased *zona fasciculata* expression or abnormal function of "eutopic" 5-HT<sub>4</sub> receptor (48). However, a possible age-related sensitivity of normal adrenal gland to direct SSRI stimulation cannot be ruled out, although our present data could simply reflect the small number of subjects enrolled in our study.

Interestingly, we also found a precocious decline in DHEA secretion across lifespan, starting from middle age, where the hormonal levels were similar to those in aging. This indicates that the reduction in DHEA synthesis and secretion, which has been hypothesized to reflect a selective age-related atrophy of the reticularis zone (46), starts before aging. DHEA secretion is usually very sensitive to the increase in ACTH concentrations, either after administration of exogenous ACTH or in response to endogenous ACTH release (49-51). In our study, in spite of a significant ACTH response to CT in all groups, no DHEA response was recorded, although a trend toward increase was observed in middle age, where ACTH reached the highest levels. This is likely to reflect the small number

of subjects studied, although a direct action of serotonergic compounds on adrenal gland cannot be ruled out. Finally, our findings did not show a significant effect of CT infusion on either PRL or GH secretion across lifespan, in agreement with controversial data previously reported (12, 13). Concerning PRL secretion, a possible sex-related influence of SSRI on lactotrope function can be hypothesized. In fact, most previous studies, which demonstrated a significant PRL response to different 5HT-agonists, referred to females only, whereas no significant PRL response to D-fenfluramine was reported in males by some authors (52, 53). Moreover, two other possible explanations can be taken into account: first, we performed the test in the morning, while previous studies performed the test in the afternoon, to avoid the morning decline in plasma PRL and cortisol levels (28, 30, 35); second, the rate of CT infusion was smaller in our than in previous studies, which used faster infusion rates, up to 20 mg in 15 min (36).

In conclusion, our study demonstrated that corticotrope response to CT is age-dependent in normal men, being clearly amplified in middle age with a progressive decline with advancing age. This suggests precocious changes in the serotonergic neuroendocrine control during human lifespan, possibly reflecting age-related changes in 5HT receptor expression and/or sensitivity. These data also indicate that CT is a useful tool to evaluate the age-dependent serotonergic function in humans.

## ACKNOWLEDGMENTS

### Disclosure statement

Nothing to declare.

## REFERENCES

1. Andrews MH, Kostaki A, Setiawan E, et al. Developmental regulation of the 5-HT<sub>7</sub> serotonin receptor and transcription factor NGF1-A in the fetal guinea-pig limbic system: influence of GCs. *J Physiol* 2004, 555: 659-70.
2. Lowry CA. Functional subsets of serotonergic neurones: implications for control of the hypothalamic-pituitary-adrenal axis. *J Neuroendocrinol* 2002, 14: 911-23.
3. Erdeljan P, MacDonald JF, Matthews SG. Glucocorticoids and serotonin alter glucocorticoid receptor (GR) but not mineralocorticoid receptor (MR) mRNA levels in fetal mouse hippocampal neurons, in vitro. *Brain Res* 2001, 896: 130-6.
4. Meaney MJ, Diorio J, Francis D, et al. Postnatal handling increases the expression of cAMP-inducible transcription factors in the rat hippocampus: the effects of thyroid hormones and serotonin. *J Neurosci* 2004, 20: 3926-35.
5. Andrews MH, Matthews SG. Programming of the hypothalamo-pituitary-adrenal axis: serotonergic involvement. *Stress* 2004, 7: 15-27.
6. Dinan TG. Serotonin and the regulation of hypothalamic-pituitary-adrenal axis function. *Life Sci* 1996, 58: 1683-94.
7. Fuller RW, Snoddy HD. Serotonin receptor subtypes involved in the elevation of serum corticosterone concentration in rats by direct and indirect-acting serotonin agonists. *Neuroendocrinology* 1990, 52: 206-11.
8. Heisler LK, Pronchuk N, Nonogaki K, et al. Serotonin activates the hypothalamic-pituitary-adrenal axis via serotonin 2c receptor stimulation. *J Neurosci* 2007, 27: 6956-64.
9. Bagdy G, Calogero AE, Aulakh CS, Szemeredi K, Murphy DL. Long-term cortisol treatment impairs behavioral and neuroendocrine responses to 5-HT<sub>1</sub> agonists in the rat. *Neuroendocrinology* 1989, 50: 241-7.
10. Di Sciuillo A, Bluet-Pajot MT, Mounier F, Oliver C, Schmidt B, Kordon C. Changes in anterior pituitary hormone levels after serotonin 1A receptor stimulation. *Endocrinology* 1997, 127: 567-72.

11. Owens MJ, Knight DL, Ritchie JC, Nemeroff CB. The 5-hydroxytryptamine<sub>2</sub> agonist, (±)-1-(2,5-dimethoxy-4-bromophenyl)-2-amino-propane stimulates the hypothalamic-pituitary-adrenal (HPA) axis. I. Acute effects on HPA axis activity and corticotrophin-releasing factor-containing neurons in the rat brain. *J Pharmacol Exp Ther* 1991, 256: 787-94.
12. Power AC, Cowen PJ. Neuroendocrine challenge tests: assessment of 5-HT function in anxiety and depression. *Mol Aspects Med* 1992, 1: 205-20.
13. Raap DK, Van de Kar LD. Selective serotonin reuptake inhibitors and neuroendocrine function. *Life Sci* 1999, 65: 1217-35.
14. Lowe SL, Yeo KP, Teng L, et al. L-5-Hydroxytryptophan augments the neuroendocrine response to a SSRI. *Psychoneuroendocrinology* 2006, 31: 473-84.
15. Arora RC, Gulati A, Crayton JW. Aging and <sup>3</sup>H-paroxetine binding in rat brain: effect of imipramine and tetrahydroacridine. *Life Sci* 1993, 52: 1767-75.
16. Yau JL, Kelly PA, Olsson T, Noble J, Seckl JR. Chronic amitriptyline administration increases serotonin transporter binding sites in the hippocampus of aged rats. *Neurosci Lett* 1999, 261: 183-5.
17. Gross-Isseroff R, Salama D, Israeli M, Biegon A. Autoradiographic analysis of age-dependent changes in serotonin 5-HT<sub>2A</sub> receptors of the human brain postmortem. *Brain Res* 1990, 19: 223-7.
18. Arranz B, Eriksson A, Møllerup E, Plenge P, Marcusson J. Effect of aging in human cortical pre- and postsynaptic serotonin binding sites. *Brain Res* 1993, 620: 163-6.
19. Wong D, Wagner H, Dannals R, et al. Effects of age on dopamine and serotonin receptors measured by positron emission tomography in living human brain. *Science* 1984, 226: 226: 1393-6.
20. Tauscher J, Verhoeff NP, Christensen BK, et al. Serotonin 5-HT<sub>1A</sub> receptor binding potential declines with age as measured by [<sup>11</sup>C]WAY-100635 and PET. *Neuropsychopharmacology* 2001 24: 522-30.
21. Sheline YI, Mintun MA, Moerlein SM, Snyder AZ. Greater loss of 5-HT(2A) receptors in midlife than in late life. *Am J Psychiatry* 2002, 159: 430-5.
22. Baeken C, D'Haenen H, Flamen P, et al. <sup>123</sup>I-5-I-R91150, a new single-photon emission tomography ligand for 5-HT<sub>2A</sub> receptors: influence of age and gender in healthy subjects. *Eur J Nucl Med* 1998, 525: 1617-22.
23. Møller M, Jakobsen S, Gjedde A. Parametric and regional maps of free serotonin 5HT<sub>1A</sub> receptor sites in human brain as function of age in healthy humans. *Neuropsychopharmacology* 2007, 32: 1707-14.
24. McBride PA, Tierney H, DeMeo M, Chen JS, Mann JJ. Effects of age and gender on CNS serotonergic responsivity in normal adults. *Biol Psychiat* 1990, 27: 1143-55.
25. Gelfin Y, Lerer B, Lesch KP, Gorfine M, Allolio B. Complex effects of age and gender on hypothalamic, adrenocorticotrophic hormone and cortisol responses to ipsapirone challenge in normal subjects. *Psychopharmacology* 1995, 120: 356-64.
26. Lerer B, Gillon D, Lichtenberg P, Gorfine M, Gelfin Y, Shapira B. Interrelationship of age, depression, and central serotonergic function: evidence from fenfluramine challenge studies. *Int Psychogeriatr* 1996, 8: 83-102.
27. O'Hara R, Schröder CM, Mahadevan R, et al. Serotonin transporter polymorphism, memory, and hippocampal volume in the elderly: association and interaction with cortisol. *Mol Psychiatry* 2007, 12: 544-55.
28. Seifritz E, Baumann P, Müller MJ, et al. Neuroendocrine effects of a 20-mg citalopram infusion in healthy males. A placebo-controlled evaluation of citalopram as 5-HT function probe. *Neuropsychopharmacology* 1996, 14: 253-63.
29. Henning J, Netter P. Oral application of citalopram (20 mg) and its usefulness for neuroendocrine challenge tests. *Int J Neuropsychopharmacol* 2002, 5: 67-71.
30. Attenburrow MJ, Mitter PR, Whale R, Terao T, Cowen PJ. Low-dose citalopram as a 5-HT neuroendocrine probe. *Psychopharmacology (Berl)* 2001, 155: 323-6.
31. Flory JD, Manuck SB, Perel JM, Muldoon MF. A comparison of d, l-fenfluramine and citalopram challenges in healthy adults. *Psychopharmacology (Berl)* 2004, 174: 376-80.
32. Bhagwagar Z, Hafizi S, Cowen PJ. Acute citalopram administration produces correlated increases in plasma and salivary cortisol. *Psychopharmacology (Berl)* 2002, 163: 118-20.
33. Pariante CM, Papadopoulos AS, Poon L, et al. Four day of citalopram increase suppression of cortisol secretion by prednisolone in healthy volunteers. *Psychopharmacology (Berl)* 2004, 177 : 200-6.
34. Lotrich FE, Bies R, Muldoon MF, Manuck SB, Smith GS, Pollock BG. Neuroendocrine response to intravenous citalopram in healthy control subjects: pharmacokinetic influences. *Psychopharmacology (Berl)* 2005, 178: 268-75.
35. Bhagwagar Z, Whale R, Cowen PJ. State and trait abnormalities in serotonin function in major depression. *Br J Psychiatry*, 2002, 180: 24-8.
36. Kapitaný T, Schindl M, Schindler SD, et al. The citalopram challenge test in patients with major depression and in healthy controls. *Psychiatry Res* 1999, 88: 75-88.
37. Pavlov EP, Harman SM, Chrousos GP, Loriaux DL, Blackman MR. Responses of plasma adrenocorticotropin, cortisol, and dehydroepiandrosterone to ovine corticotropin-releasing hormone in healthy aging men. *J Clin Endocrinol Metab* 1986, 62: 767-72.
38. Dodt C, Theine K, Utthgenannt D, Born J, Fehm HL. Basal secretory activity of the hypothalamo-pituitary-adrenocortical axis is enhanced in healthy elderly. An assessment during undisturbed night-time sleep. *Eur J Endocrinol* 1994, 131: 443-50.
39. Van Cauter E, Leproult R, Kupfer DJ. Effects of gender and age on the levels and circadian rhythmicity of plasma cortisol. *J Clin Endocrinol Metab* 1996, 81: 2468-73.
40. Deuschle M, Gotthardt U, Schweiger U, et al. With aging in humans the activity of the hypothalamus-pituitary-adrenal system increases and its diurnal amplitude flattens. *Life Sci* 1997, 61: 2239-46.
41. Touitou Y, Sulon J, Bogdan A, et al. Adrenal circadian system in young and elderly human subjects: a comparative study. *J Endocrinol* 1982, 93: 201-10.
42. Waltman C, Blackman MR, Chrousos GP, Riemann C, Harman SM. Spontaneous and glucocorticoid-inhibited adrenocorticotrophic hormone and cortisol secretion are similar in healthy young and old men. *J Clin Endocrinol Metab* 1991, 73: 495-502.
43. Dodt C, Dittmann J, Hruby J, et al. Different regulation of adrenocorticotropin and cortisol secretion in young, mentally healthy elderly and patients with senile dementia of Alzheimer's type. *J Clin Endocrinol Metab* 1991, 72: 272-6.
44. Meijer OC, de Lange EC, Breimer DD, de Boer AG, Workel JO, de Kloet ER. Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P-glycoprotein knockout mice. *Endocrinology* 1998, 139: 1789-93.
45. Sherman B, Wysham C, Pfohl B. Age-related changes in the circadian rhythm of plasma cortisol in man. *J Clin Endocrinol Metab* 1985, 61: 439-43.
46. Parker CR, Mixon RL, Brissie RM, Grizzle WE. Aging alters zonation in the adrenal cortex of men. *J Clin Endocrinol Metab* 1997, 82: 3898-901.
47. Mondelli V, Gianotti L, Picu A, et al. Neuroendocrine effects of citalopram infusion in anorexia nervosa. *Psychoneuroendocrinology* 2006, 31: 1139-48.
48. Lacroix A, Ndiaye N, Tremblay J, Hamet P. Ectopic and abnormal hormone receptors in adrenal Cushing's syndrome. *Endocr Rev* 2001, 22: 75-110.
49. Parker CR Jr, Azziz R, Potter HD, Boots LR. Adrenal androgen production in response to adrenocorticotropin infusions in men. *Endocr Res* 1996, 22: 717-22.
50. Arvat E, Di Vito L, Lanfranco F, et al. Stimulatory effect of adrenocorticotropin on cortisol, aldosterone, and dehydroepiandrosterone secretion in normal humans: dose-response study. *J Clin Endocrinol Metab* 2000, 85: 3141-6.
51. Giordano R, Bo M, Pellegrino M, et al. Hypothalamus-pituitary-adrenal hyperactivity in human aging is partially refractory to stimulation by mineralocorticoid receptor blockade. *J Clin Endocrinol Metab* 2005, 90: 5656-62.
52. Goodwin GM, Murray CL, Bancroft J. Oral D-fenfluramine and neuroendocrine challenge: problems with the 30 mg dose in men. *J Affect Disord* 1994, 30: 117-22.
53. Ramasubbu R, Flint A, Brown G, Awad G, Kennedy S. Neurohormonal responses to D-fenfluramine in healthy elderly subjects. A placebo-controlled study. *Psychoneuroendocrinology* 2000, 25: 139-50.